Repligen (NASDAQ:RGEN) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Repligen (NASDAQ:RGEN) released its earnings results on Tuesday. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10, FiscalAI reports. The firm had revenue of $194.26 million for the quarter, compared to analysts’ expectations of $192.05 million. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The business’s revenue for the quarter was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.39 earnings per share. Repligen updated its FY 2026 guidance to 1.970-2.050 EPS.

Here are the key takeaways from Repligen’s conference call:

• Repligen reported strong Q1 results with $194M revenue (15% reported, 11% organic), 160 bps adjusted operating margin expansion, and raised full‑year adjusted EPS guidance to $1.97–$2.05.
• Management launched a Transformation Office to accelerate cost, manufacturing and IT/AI improvements, targeting at least 1 point of annualized margin benefit by end‑2027 and advancing the path to 30% adjusted EBITDA by 2030 (with ~$5–6M of non‑recurring charges).
• China and Asia Pacific momentum picked up meaningfully—China revenues nearly doubled in Q1 and the company signed an OEM partnership to expand local manufacturing and competitiveness beginning in 2027.
• Franchise strength was broad‑based and higher‑margin—analytics grew 50%+ (now guided to 20%+ for 2026), chromatography rose >25% (now guided >20%), and proteins delivered mid‑teens growth with expectations of low double‑digit growth for the year.
• Filtration/ATF growth was moderated for 2026 due to specific customer timing and a gene‑therapy headwind; the divestiture of the loss‑making Polymem business removes about $7M of FY revenue even as it improves margin outlook.

Repligen Trading Up 0.6%

Shares of Repligen stock traded up $0.81 during trading on Thursday, hitting $126.57. The company’s stock had a trading volume of 668,933 shares, compared to its average volume of 887,353. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.20 and a quick ratio of 7.12. Repligen has a 52 week low of $109.50 and a 52 week high of $175.77. The stock has a market cap of $7.14 billion, a price-to-earnings ratio of 140.63, a price-to-earnings-growth ratio of 2.45 and a beta of 1.09. The stock has a 50-day moving average price of $121.16 and a two-hundred day moving average price of $144.31.

Institutional Trading of Repligen

Institutional investors have recently modified their holdings of the business. Measured Wealth Private Client Group LLC bought a new stake in shares of Repligen in the third quarter worth $29,000. Los Angeles Capital Management LLC bought a new stake in shares of Repligen in the fourth quarter worth $36,000. Itau Unibanco Holding S.A. grew its stake in shares of Repligen by 38.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares during the last quarter. Johnson Financial Group Inc. bought a new stake in shares of Repligen in the third quarter worth $65,000. Finally, Wilmington Savings Fund Society FSB grew its stake in shares of Repligen by 2,750.0% in the third quarter. Wilmington Savings Fund Society FSB now owns 513 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 495 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RGEN. Rothschild & Co Redburn set a $160.00 price objective on shares of Repligen and gave the stock a “buy” rating in a research report on Friday, April 17th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. JPMorgan Chase & Co. cut their price objective on Repligen from $180.00 to $165.00 and set an “overweight” rating on the stock in a report on Wednesday. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a report on Wednesday, February 25th. Finally, UBS Group cut their price target on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $169.62.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.